Aelmar Pharmaceutical Private Limited
Pharmaceutical trading and distribution company established in 2019.
2019 | Hyderabad, Telangana (India) | Active
Aelmar Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -8.02%
- Profit Growth -48.21%
- Ebitda 36.51%
- Net Worth 16.95%
- Total Assets 27.87%
About Aelmar Pharmaceutical
Aelmar Pharmaceutical Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 29 March 2019 (Five years and 11 months 2 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Aditya Patil and Abdul Abdul serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74990TG2019PTC131714
- Company No.
131714
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Mar 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Pharma
Who are the key members and board of directors at Aelmar Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aditya Patil  | Director | 29-Mar-2019 | Current |
| Abdul Abdul | Director | 29-Mar-2019 | Current |
Financial Performance of Aelmar Pharmaceutical.
Aelmar Pharmaceutical Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 8.02% decrease. The company also saw a substantial fall in profitability, with a 48.21% decrease in profit. The company's net worth Soared by an impressive increase of 16.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aelmar Pharmaceutical?
Unlock access to Aelmar Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aelmar Pharmaceutical?
Unlock and access historical data on people associated with Aelmar Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aelmar Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aelmar Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
